Pinkerton Wealth LLC Purchases 1,850 Shares of Amgen Inc. $AMGN

Pinkerton Wealth LLC boosted its position in Amgen Inc. (NASDAQ:AMGN) by 11.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,976 shares of the medical research company’s stock after buying an additional 1,850 shares during the quarter. Pinkerton Wealth LLC’s holdings in Amgen were worth $5,073,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of AMGN. Banque Cantonale Vaudoise lifted its position in Amgen by 2.3% during the 3rd quarter. Banque Cantonale Vaudoise now owns 17,333 shares of the medical research company’s stock worth $4,892,000 after acquiring an additional 392 shares during the last quarter. Aull & Monroe Investment Management Corp grew its position in shares of Amgen by 1.7% in the third quarter. Aull & Monroe Investment Management Corp now owns 9,445 shares of the medical research company’s stock valued at $2,665,000 after purchasing an additional 161 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Amgen by 10.1% in the third quarter. Russell Investments Group Ltd. now owns 267,101 shares of the medical research company’s stock worth $74,990,000 after purchasing an additional 24,446 shares during the period. Schroder Investment Management Group lifted its position in shares of Amgen by 17.0% during the 3rd quarter. Schroder Investment Management Group now owns 333,529 shares of the medical research company’s stock worth $91,377,000 after purchasing an additional 48,384 shares during the last quarter. Finally, Gerber Kawasaki Wealth & Investment Management lifted its position in shares of Amgen by 8.4% during the 3rd quarter. Gerber Kawasaki Wealth & Investment Management now owns 7,224 shares of the medical research company’s stock worth $2,039,000 after purchasing an additional 557 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 2.0%

Shares of AMGN stock opened at $376.97 on Tuesday. The firm has a fifty day moving average of $354.21 and a 200-day moving average of $323.38. The stock has a market cap of $203.21 billion, a price-to-earnings ratio of 26.49, a P/E/G ratio of 3.67 and a beta of 0.45. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s revenue was up 8.6% on a year-over-year basis. During the same period in the previous year, the business earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is presently 70.84%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Argus raised their target price on Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a report on Friday, February 6th. Scotiabank began coverage on Amgen in a report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price target for the company. Royal Bank Of Canada increased their price objective on Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research report on Wednesday, February 4th. Barclays assumed coverage on shares of Amgen in a research note on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price objective on the stock. Finally, TD Cowen reiterated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Amgen presently has a consensus rating of “Hold” and an average price target of $354.17.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.